Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myelomaSally Moore, Kwee Yong, Neil Rabin et al.|European Journal Of Haematology|2013Cited by 14
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon StudyKwee Yong, Roger G. Owen, Rakesh Popat et al.|Blood|2019Cited by 8
PF599 EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIALElizabeth H. Phillips, Kwee Yong, William Wilson et al.|HemaSphere|2019Cited by 0
PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon StudyCeri Bygrave, Kwee Yong, Manil Subesinghe et al.|Blood|2021Cited by 0